The DCTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DCTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The DCTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View DCTH Detailed Price Forecast - CNN Money||View DCTH Detailed Summary - Google Finance|
|View DCTH Detailed Summary - Yahoo! Finance||View DCTH Stock Research & Analysis - Zacks.com|
|View DCTH Trends & Analysis - Trade-Ideas||View DCTH Major Holders - Barrons|
|View DCTH Call Transcripts - NASDAQ||View DCTH Breaking News & Analysis - Seeking Alpha|
|View DCTH Annual Report - CompanySpotlight.com||View DCTH OTC Short Report - OTCShortReport.com|
|View DCTH Fundamentals - TradeKing||View DCTH SEC Filings - Bar Chart|
|View Historical Prices for DCTH - The WSJ||View Performance/Total Return for DCTH - Morningstar|
|View the Analyst Estimates for DCTH - MarketWatch||View the Earnings History for DCTH - CNBC|
|View the DCTH Earnings - StockMarketWatch||View DCTH Buy or Sell Recommendations - MacroAxis|
|View the DCTH Bullish Patterns - American Bulls||View DCTH Short Pain Metrics - ShortPainBot.com|
|View DCTH Stock Mentions - StockTwits||View DCTH Stock Mentions - PennyStockTweets|
|View DCTH Stock Mentions - Twitter||View DCTH Investment Forum News - Investor Hub|
|View DCTH Stock Mentions - Yahoo! Message Board||View DCTH Stock Mentions - Seeking Alpha|
|View Insider Transactions for DCTH - SECform4.com||View Insider Transactions for DCTH - Insider Cow|
|View DCTH Major Holdings Summary - CNBC||View Insider Disclosure for DCTH - OTC Markets|
|View Insider Transactions for DCTH - Yahoo! Finance||View Institutional Holdings for DCTH - NASDAQ|
|View DCTH Stock Insight & Charts - FinViz.com||View DCTH Investment Charts - StockCharts.com|
|View DCTH Stock Overview & Charts - BarChart||View DCTH User Generated Charts - Trading View|
Delcath Systems to Present at the 8th Annual LD Micro Invitational
Posted on Tuesday May 29, 2018
Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 12:00pm PST / 3:00pm EST. Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems, will be presenting and meeting with investors. Dr. Simpson’s presentation will be webcast live on the internet and can be accessed by visiting the News and Events section of the Company’s website at www.delcath.com.
Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event
Posted on Tuesday May 22, 2018
Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to sponsor A Cure In Sight and its first annual Looking for a Cure 5K charity event. A Cure in Sight is a patient advocacy group dedicated to providing patient services for ocular melanoma patients and their families. Looking for a Cure was held in Palo Alto, CA at the Byers Eye Institute on May 20, 2018. The event raised over $15,000 to support A Cure In Sight’s efforts in research, awareness and financial support programs for ocular melanoma patients.
Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases
Posted on Wednesday May 16, 2018
Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the German Guidelines Program in Oncology (GGPO) has included treatment with Delcath’s CHEMOSAT® in the German national treatment guidelines for liver metastases from melanoma. This inclusion of treatment with CHEMOSAT is in the S3 Guidelines, which represents the highest level within the classification of the guidelines indicating that it is based on evidence and consensus within the German clinical community. The GGPO’s update was based on its evaluation of published data on treatment with CHEMOSAT as a loco-regional treatment for melanoma liver metastases. Following this evaluation, and after soliciting additional feedback from the oncology community in Germany, treatment with CHEMOSAT was classified with Evidence Level 1B, indicating the second highest level of evidence.
Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology
Posted on Monday May 14, 2018
Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s PHP Therapy was featured in a Video Learning Session presented at the Annual Meeting of the European Conference of Interventional Oncology (ECIO). Dr. M.C. Burgmans of Leiden University Medical Center (LUMC) in the Netherlands presented the training in the main auditorium session dedicated to advances in liver cancer therapies. Dr. Burgmans presented an overview of the Percutaneous Hepatic Perfusion (PHP) procedure, discussed the therapy’s developmental history, demonstrating how to perform the procedure, as well as outlining its potential in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, and highlighting ongoing clinical research.